In conclusion, therapy with UDCA in NASH patients may lead to a reduction in GGT and ALT levels when there are polymorphisms in the genes encoding bile acid transporters and regulation. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.